Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI South Korea ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while iShares MSCI South Korea ETF trades at $180.42. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EWY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $219.20 |
52-Week Low | $4.17 | $70.65 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
The iShares MSCI South Korea ETF (EWY) trades at $189.85, up 5.33% over 24 hours, amid volatile South Korean equity markets. Technical indicators show a bearish trend with key support at $185 and resistance at $192. Recent news highlights strong AI-driven semiconductor demand boosting South Korean stocks, but weak EV battery demand and market volatility pose headwinds.
EWY's outlook hinges on AI memory demand and Samsung's performance, with potential gains from SK Hynix's U.S. listing. Risks include semiconductor cycle volatility and foreign investor selling. The ETF remains a high-beta play on South Korea's tech sector, requiring careful risk management amid elevated market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
